文献速递流行病学与生物统计

成人青光眼筛查:美国预防服务工作组更新证据报告与系统综述

Screening for Glaucoma in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
PubMed 文献 · JAMA · 2022-01-01

本系统综述更新2013年证据,纳入83项研究(N=75 887),评估成人开角型青光眼筛查获益与危害。一项RCT(n=616)显示对衰弱老年人筛查与不筛查相比视力结局无差异,但跌倒风险显著增加(RR 1.31)。筛查试验可识别青光眼患者,治疗与降低青光眼进展风险相关,但视觉结局、生活质量和功能改善的证据仍缺乏。

要点

  • 对衰弱老年人筛查与不筛查相比视力结局无差异,但跌倒风险显著增加(RR 1.31)。
  • 光谱域光学相干断层扫描诊断青光眼敏感度0.79、特异度0.92;眼压测量敏感度低(0.48)。
  • 药物治疗与降低青光眼进展风险相关(RR 0.68),但视觉结局和生活质量改善证据缺乏。

核心结论

  • 本综述发现青光眼筛查的直接证据有限,显示筛查与获益无关。
  • 筛查试验可识别青光眼患者,治疗与降低青光眼进展风险相关,但视觉结局、生活质量和功能改善的证据仍缺乏。

研究设计与样本

  • 系统综述纳入83项研究(N=75 887),包括30项试验和53项诊断准确性研究。
  • 检索Ovid MEDLINE、Cochrane对照试验中心注册库和Cochrane系统综述数据库至2021年2月,监测至2022年1月21日。
  • 纳入筛查、转诊和治疗的随机临床试验,以及筛查试验诊断准确性研究。
  • 一名研究者提取数据,另一名核对准确性;两名研究者独立评估研究质量。

主要发现

  • 一项RCT(n=616)发现对衰弱老年人筛查与不筛查相比视力结局无差异,但跌倒风险显著增加(RR 1.31 [95% CI, 1.13-1.50])。
  • 无研究评估转诊至眼健康专业人员的效果。
  • 光谱域光学相干断层扫描(15项研究,n=4242)诊断青光眼的敏感度为0.79(95% CI, 0.75-0.83),特异度为0.92(95% CI, 0.87-0.96)。
  • Humphrey视野分析仪(6项研究,n=11 244)的敏感度为0.87(95% CI, 0.69-0.95),特异度为0.82(95% CI, 0.66-0.92);眼压测量(13项研究,n=32 892)敏感度低(0.48 [95% CI, 0.31-0.66])。
  • 针对高眼压和未治疗青光眼的药物治疗与安慰剂相比,显著降低眼压和降低青光眼进展可能性(7项试验,n=3771;RR 0.68 [95% CI, 0.49-0.96];绝对风险差-4.2%),但1项试验(n=461)发现视力、生活质量或功能无差异;选择性激光小梁成形术与药物治疗结局相似(4项试验,n=957)。

局限性

  • 本综述发现青光眼筛查的直接证据有限,显示筛查与获益无关。
  • 视觉结局、生活质量和功能改善的证据仍缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Two 2013 systematic reviews to inform the US Preventive Services Task Force (USPSTF) found insufficient evidence to assess benefits and harms of screening for primary open-angle glaucoma (OAG) in adults. OBJECTIVE: To update the 2013 reviews on screening for glaucoma, to inform the USPSTF. DATA SOURCES: Ovid MEDLINE, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews (to February 2021); surveillance through January 21, 2022. STUDY SELECTION: Randomized clinical trials (RCTs) of screening, referral, and treatment; and studies of screening test diagnostic accuracy. DATA EXTRACTION AND SYNTHESIS: One investigator abstracted data and a second checked accuracy. Two investigators independently assessed study quality. RESULTS: Eighty-three studies (N = 75 887) were included (30 trials and 53 diagnostic accuracy studies). One RCT (n = 616) found screening of frail elderly persons associated with no difference in vision outcomes vs no screening but with significantly greater falls risk (relative risk [RR], 1.31 [95% CI, 1.13-1.50]). No study evaluated referral to an eye health professional. For glaucoma diagnosis, spectral domain optical coherence tomography (providing high-resolution cross-sectional imaging; 15 studies, n = 4242) was associated with sensitivity of 0.79 (95% CI, 0.75-0.83) and specificity of 0.92 (95% CI, 0.87-0.96) and the Humphrey Visual Field Analyzer (for perimetry, or measurement of visual fields; 6 studies, n = 11 244) with sensitivity of 0.87 (95% CI, 0.69-0.95) and specificity 0.82 (95% CI, 0.66-0.92); tonometry (for measurement of intraocular pressure; 13 studies, n = 32 892) had low sensitivity (0.48 [95% CI, 0.31-0.66]). Medical therapy for ocular hypertension and untreated glaucoma was significantly associated with decreased intraocular pressure and decreased likelihood of glaucoma progression (7 trials, n = 3771; RR, 0.68 [95% CI, 0.49-0.96]; absolute risk difference -4.2%) vs placebo, but 1 trial (n = 461) found no differences in visual acuity, quality of life, or function. Selective laser trabeculoplasty and medical therapy had similar outcomes (4 trials, n = 957). CONCLUSIONS AND RELEVANCE: This review found limited direct evidence on glaucoma screening, showing no association with benefits. Screening tests can identify persons with glaucoma and treatment was associated with a lower risk of glaucoma progression, but evidence of improvement in visual outcomes, quality of life, and function remains lacking.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Chou R, Selph S, Blazina I, et al. Screening for Glaucoma in Adults: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2022. PMID: 35608575. doi:10.1001/jama.2022.6290

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。